Low Use and Adherence to Maintenance Medication in Chronic Obstructive Pulmonary Disease in the General Population

Journal of General Internal Medicine

Volumn 30, Issue 1, 2015, Pages 51-59

  Ingebrigtsen, Truls S ^a,b,c   Marott, Jacob L ^b   Nordestgaard, Børge G ^b,c   Lange, Peter ^b,c,d,e   Hallas, Jesper ^f   Dahl, Morten ^g   Vestbo, Jørgen ^a,h  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g Rigshospitalet   (Denmark)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

COPD; GOLD; long acting medication; severity

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING DRUG; DRUG COMBINATION; GLUCOCORTICOID;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LEISURE; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; RESPIRATORY AIRFLOW; SENSITIVITY ANALYSIS; DENMARK; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG UTILIZATION; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTER; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; DENMARK; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG UTILIZATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; SEVERITY OF ILLNESS INDEX;

EID: 84939228324     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-3029-0     Document Type: Article

References (32)

1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364(9434):613–20.
2. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.
4. Ingebrigtsen TS, Marott JL, Vestbo J, et al. Characteristics of undertreatment in COPD in the general population. Chest. 2013;144(6):1811–8.
5. Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin. 2011;27(7):1425–9.
6. Krigsman K, Nilsson JL, Ring L. Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions. Pharmacoepidemiol Drug Saf. 2007;16(4):441–8.
7. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939–43.
8. Bryant J, McDonald VM, Boyes A, Sanson-Fisher R, Paul C, Melville J. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res. 2013;14(1):109.
9. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309(22):2353–61.
10. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.
11. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445–8.
12. The Danish National Patient Register. Available at: http://www.ssi.dk/Sundshedsdataogit/Registre/Landspatientregisteret.aspx. Accessed July 18, 2014.
13. Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509–16.
14. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. List of DDDs combined products. Available at: http://www.whocc.no/ddd/list_of_ddds_combined_products/. Accessed July 18, 2014.
15. WHO Collaborating Centre for Drug Statistics Methodology. Available at: http://www.whocc.no. Accessed July 18, 2014.
16. The Comprehensive R Archive Network: Available at: http://cran.r-project.org/. Accessed July 18, 2014.
17. Crawley M, The R. book. Imperial College London at Silwood Park. John Wiley & Sons: London, UK; 2007.
18. Yang Y, Thumula V, Pace PF, Banahan BF 3rd, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009;31(10):2178–88. discussion 2150–1.
19. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(3):371–84.
20. Laforest L, Denis F, Van Ganse E, et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J. 2010;19(2):148–54.
21. Touchette DR, Shapiro NL. Medication Compliance, Adherence, and Persistence: Current Status of Behavioral and Educational Interventions to Improve Outcomes. J Manag Care Pharm. 2008;14(6):S2–S10.
22. Khdour MR, Hawwa AF, Kidney JC, Smyth BM, McElnay JC. Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease (COPD). Eur J Clin Pharmacol. 2012;68(10):1365–73.
23. Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458–65.
24. Lange P, Marott JL, Vestbo J, Ingebrigtsen TS, Nordestgaard BG. Socioeconomic Status and Prognosis of COPD in Denmark. COPD. 2014.
25. Huetsch JC, Uman JE, Udris EM, Au DH. Predictors of adherence to inhaled medications among Veterans with COPD. J Gen Intern Med. 2012;27(11):1506–12.
26. VanderSchaaf K, Olson KL, Billups S, Hartsfield CL, Rice M. Self-reported inhaler use in patients with chronic obstructive pulmonary disease. Respir Med. 2010;104(1):99–106.
27. Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J. 2011;32(19):2365–75.
28. Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010;182(7):673–8.
29. Statistics from Statens Serum Institut (sale of drugs in Denmark during 1996–2013). Available at: www.medstat.dk. Accessed July 18, 2014.
30. Hirth RA, Greer SL, Albert JM, Young EW, Piette JD. Out-of-pocket spending and medication adherence among dialysis patients in twelve countries. Health Aff. 2008;27(1):89–102.
31. Tøttenborg S, Topp M, Ingebrigtsen TS, Lange P. Physicians should increase focus on poor medicine adherence among chronically ill patients (Danish title: Læger bør øge fokus på medicinadhærens blandt kronisk syge). Ugeskr Laeger. 2013 [e-pub ahead of print]. Available at: http://ugeskriftet.dk/files/ugeskriftet.dk/vp05130287.pdf. Accessed August 24, 2014.
32. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids–implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221.